Idnatx Capsule contains Enzalutamide 40 mg, a nonsteroidal antiandrogen used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide functions by inhibiting androgen receptor signaling, thereby preventing the growth and proliferation of prostate cancer cells that depend on androgens for survival. It competitively binds to androgen receptors, inhibits nuclear translocation of the receptor, and impedes DNA binding and coactivator recruitment, effectively reducing tumor progression. Idnatx Capsule is indicated for patients with advanced prostate cancer who have shown resistance to conventional androgen deprivation therapy. The medication is administered orally, with dosing tailored according to clinical response and tolerability. Common adverse effects include fatigue, hypertension, hot flashes, and musculoskeletal pain, while serious but less frequent risks involve seizures and cardiovascular events. Regular monitoring of liver function, blood pressure, and electrolyte levels is recommended during treatment. Idnatx Capsule should be used under strict medical supervision, considering potential drug interactions and contraindications, particularly in patients with a history of seizures or cardiovascular disease. This therapeutic agent represents a significant advancement in managing advanced prostate cancer by targeting androgen receptor pathways more effectively than earlier treatments.